Mannkind Corporation (MNKD) 1.61 $MNKD
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.91 (+0.42), CMRX: 5.11 (+0.14), GERN: 2.92 (+0.05), CYTX: 0.21 (+0.01), CLDX: 3.78 (+0.18), SGMO: 6.05 (+0.31), PTCT: 6.44 (+0.35), ATHX: 2.25 (+0.02), MNKD: 1.61 (-0.07)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 4.36 (+0.11), BIND: 2.20 (-0.01), MNKD: 1.61 (-0.07), KERX: 4.67 (-0.04)
MannKind (MNKD) in Focus: Stock Moves 5.5% Higher
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 7:40AM CDT
MannKind Corp. (MNKD) saw its shares rise above 5% in the last trading session.
MNKD: 1.61 (-0.07)
Does Valeant Pharmaceuticals' Downward Spiral Signal The End of An Era?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 20, 1:04PM CDT
Source: Sage Ross via Wikimedia Valeant Pharmaceuticals has perhaps become the poster child for the drug pricing debate that's weighing heavily on the pharmaceutical industry at the moment. After all, Valeant's dramatic rise and fall over the...
MNK: 61.28 (+1.37), VRX: 26.30 (-0.77), MNKD: 1.61 (-0.07)
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 18, 8:03AM CDT
Image source: Flickr user Hobvias Sudoneighm. The easiest investment strategy, and the one that's proven to work best over the long run, is to pick out high-quality businesses and hold them for long periods of time. However, for some investors the...
ZIOP: 7.42 (+0.17), INSY: 15.99 (+0.11), SRPT: 19.52 (+0.25), RLYP: 13.55 (+0.11), MNKD: 1.61 (-0.07)
MannKind (MNKD) Jumps: Stock Adds 17.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 7:15AM CDT
MannKind Corp. (MNKD) shares rose nearly 18% in the last trading session.
ANIK: 44.72 (-0.26), MNKD: 1.61 (-0.07)
MannKind Posts Wider-than-Expected Loss, Afrezza in Focus
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 12:29PM CDT
MannKind (MNKD) reported a loss of 17 cents per share in the fourth quarter, wider than the Zacks Consensus Estimate of a loss of 5 cents.
AMAG: 23.40 (+1.28), ANIK: 44.72 (-0.26), MNKD: 1.61 (-0.07), SNY: 40.16 (-0.53)
Why MannKind Corporation Is Dropping Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue Mar 15, 11:45AM CDT
Image source: MannKind Corporation . What: After reporting fourth-quarter and full year earnings, shares of inhaled insulin maker MannKind fell more than 10% in early morning trading, though they have since recovered a bit and are down about...
SNY: 40.16 (-0.53), MNKD: 1.61 (-0.07)
MannKind (MNKD) Stock Drops on Q4 Loss
at The Street - Tue Mar 15, 9:29AM CDT
MannKind (MNKD) stock is sinking in mid-morning trading on Tuesday after the biopharmaceutical company reported a wider-than-expected loss during the 2015 fourth quarter.
MNKD: 1.61 (-0.07)
MannKind Corporation Reports 2015 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Mon Mar 14, 6:19PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2015.
MNKD: 1.61 (-0.07)
MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer
GlobeNewswire - Mon Mar 14, 6:17PM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKind's executive leadership team.
MRK: 52.91 (-0.31), AMGN: 149.93 (+0.45), BMY: 63.88 (+0.44), MNKD: 1.61 (-0.07), NVS: 72.44 (-0.11)
MannKind (MNKD) Stock Down in After-Hours Trading on Q4 Earnings
at The Street - Mon Mar 14, 3:57PM CDT
MannKind (MNKD) stock is declining in after-hours trading on Monday after reporting its 2015 fourth quarter financial results.
MNKD: 1.61 (-0.07)
What MannKind Corporation's Failure Teaches Biotech Investors About Risk
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Mon Mar 14, 12:26PM CDT
Commercializing medicine that works in an entirely unique and new way isn't easy, and investors were reminded of that reality when partners MannKind and Sanofi SA failed to establish a foothold in diabetes for their inhalable insulin, Afrezza....
SNY: 40.16 (-0.53), MNKD: 1.61 (-0.07)
March 15 Deadline Alert: Law Offices of Howard G. Smith Reminds MannKind Corp. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Mon Mar 14, 8:30AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming March 15, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased MannKind Corp. ("MannKind" or the "Company"
(NASDAQ: MNKD) securities between August 10, 2015 and January 5, 2016, inclusive (the "Class Period". Investors who suffered losses on their investment in MannKind securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
MNKD: 1.61 (-0.07)
What's Ahead for the Week: Can FedEx Deliver Strong Results?
at The Street - Sun Mar 13, 11:15AM CDT
In addition to FedEx, Oracle, Adobe Systems and Tiffany will report quarterly earnings this coming week.
FDX: 162.72 (+1.15), DSW: 27.64 (-0.22), FOGO: 15.61 (+0.22), TIF: 73.38 (+0.79), MNKD: 1.61 (-0.07), ADBE: 93.80 (+0.02), ORCL: 40.91 (-0.06)
3 Big Risks Biotech Stocks Face
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Mar 13, 6:22AM CDT
Biotech is a notoriously risky sector. What seems like a sure success one day can easily result in debilitating failure, and companies are constantly making headlines for nosediving in price when expectations fall through. But if you're an investor...
CLDX: 3.78 (+0.18), MNKD: 1.61 (-0.07), PDLI: 3.33 (+0.16)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MannKind Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 15, 2016 - MNKD
GlobeNewswire - Fri Mar 11, 10:54AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
MNKD: 1.61 (-0.07)
March 15 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Lawsuit Against MannKind Corp.
BusinessWire - Fri Mar 11, 10:30AM CST
Glancy Prongay & Murray LLP ("GPM" reminds investors of the upcoming March 15, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class" of investors who purchased MannKind Corp. ("MannKind" or the "Company" (NASDAQ: MNKD) securities between August 10, 2015 and January 5, 2016, inclusive (the "Class Period". MannKind investors are encouraged to contact Casey Sadler, Esquire, to discuss their legal rights.
MNKD: 1.61 (-0.07)
MannKind (MNKD) Stock Spiked Ahead of Q4 Earnings
at The Street - Thu Mar 10, 3:04PM CST
MannKind (MNKD) shares closed Thursday's trading session up ahead of the company's 2015 fourth quarter financial results.
MNKD: 1.61 (-0.07)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving MannKind Corp. and a Lead Plaintiff Deadline of March 15, 2016 - MNKD
GlobeNewswire - Wed Mar 09, 9:16AM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp. (Nasdaq:MNKD) securities between August 10, 2015 and January 5, 2016.
MNKD: 1.61 (-0.07)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.91 (+0.42), CMRX: 5.11 (+0.14), GERN: 2.92 (+0.05), CYTX: 0.21 (+0.01), CLDX: 3.78 (+0.18), SGMO: 6.05 (+0.31), PTCT: 6.44 (+0.35), ATHX: 2.25 (+0.02), MNKD: 1.61 (-0.07)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 4.36 (+0.11), BIND: 2.20 (-0.01), MNKD: 1.61 (-0.07), KERX: 4.67 (-0.04)
MannKind (MNKD) in Focus: Stock Moves 5.5% Higher
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 7:40AM CDT
MannKind Corp. (MNKD) saw its shares rise above 5% in the last trading session.
MNKD: 1.61 (-0.07)
Does Valeant Pharmaceuticals' Downward Spiral Signal The End of An Era?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 20, 1:04PM CDT
Source: Sage Ross via Wikimedia Valeant Pharmaceuticals has perhaps become the poster child for the drug pricing debate that's weighing heavily on the pharmaceutical industry at the moment. After all, Valeant's dramatic rise and fall over the...
MNK: 61.28 (+1.37), VRX: 26.30 (-0.77), MNKD: 1.61 (-0.07)
Of These 5 Hated Biotech Stocks, Only 1 Is a Potential Disaster in the Making
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 18, 8:03AM CDT
Image source: Flickr user Hobvias Sudoneighm. The easiest investment strategy, and the one that's proven to work best over the long run, is to pick out high-quality businesses and hold them for long periods of time. However, for some investors the...
ZIOP: 7.42 (+0.17), INSY: 15.99 (+0.11), SRPT: 19.52 (+0.25), RLYP: 13.55 (+0.11), MNKD: 1.61 (-0.07)
MannKind (MNKD) Jumps: Stock Adds 17.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 7:15AM CDT
MannKind Corp. (MNKD) shares rose nearly 18% in the last trading session.
ANIK: 44.72 (-0.26), MNKD: 1.61 (-0.07)
MannKind Posts Wider-than-Expected Loss, Afrezza in Focus
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 12:29PM CDT
MannKind (MNKD) reported a loss of 17 cents per share in the fourth quarter, wider than the Zacks Consensus Estimate of a loss of 5 cents.
AMAG: 23.40 (+1.28), ANIK: 44.72 (-0.26), MNKD: 1.61 (-0.07), SNY: 40.16 (-0.53)
Why MannKind Corporation Is Dropping Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue Mar 15, 11:45AM CDT
Image source: MannKind Corporation . What: After reporting fourth-quarter and full year earnings, shares of inhaled insulin maker MannKind fell more than 10% in early morning trading, though they have since recovered a bit and are down about...
SNY: 40.16 (-0.53), MNKD: 1.61 (-0.07)
MannKind (MNKD) Stock Drops on Q4 Loss
at The Street - Tue Mar 15, 9:29AM CDT
MannKind (MNKD) stock is sinking in mid-morning trading on Tuesday after the biopharmaceutical company reported a wider-than-expected loss during the 2015 fourth quarter.
MNKD: 1.61 (-0.07)
MannKind Corporation Reports 2015 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Mon Mar 14, 6:19PM CDT
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2015.
MNKD: 1.61 (-0.07)
MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer
GlobeNewswire - Mon Mar 14, 6:17PM CDT
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKind's executive leadership team.
MRK: 52.91 (-0.31), AMGN: 149.93 (+0.45), BMY: 63.88 (+0.44), MNKD: 1.61 (-0.07), NVS: 72.44 (-0.11)
MannKind (MNKD) Stock Down in After-Hours Trading on Q4 Earnings
at The Street - Mon Mar 14, 3:57PM CDT
MannKind (MNKD) stock is declining in after-hours trading on Monday after reporting its 2015 fourth quarter financial results.
MNKD: 1.61 (-0.07)
What MannKind Corporation's Failure Teaches Biotech Investors About Risk
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Mon Mar 14, 12:26PM CDT
Commercializing medicine that works in an entirely unique and new way isn't easy, and investors were reminded of that reality when partners MannKind and Sanofi SA failed to establish a foothold in diabetes for their inhalable insulin, Afrezza....
SNY: 40.16 (-0.53), MNKD: 1.61 (-0.07)
March 15 Deadline Alert: Law Offices of Howard G. Smith Reminds MannKind Corp. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Mon Mar 14, 8:30AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming March 15, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased MannKind Corp. ("MannKind" or the "Company"
(NASDAQ: MNKD) securities between August 10, 2015 and January 5, 2016, inclusive (the "Class Period". Investors who suffered losses on their investment in MannKind securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights. MNKD: 1.61 (-0.07)
What's Ahead for the Week: Can FedEx Deliver Strong Results?
at The Street - Sun Mar 13, 11:15AM CDT
In addition to FedEx, Oracle, Adobe Systems and Tiffany will report quarterly earnings this coming week.
FDX: 162.72 (+1.15), DSW: 27.64 (-0.22), FOGO: 15.61 (+0.22), TIF: 73.38 (+0.79), MNKD: 1.61 (-0.07), ADBE: 93.80 (+0.02), ORCL: 40.91 (-0.06)
3 Big Risks Biotech Stocks Face
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Mar 13, 6:22AM CDT
Biotech is a notoriously risky sector. What seems like a sure success one day can easily result in debilitating failure, and companies are constantly making headlines for nosediving in price when expectations fall through. But if you're an investor...
CLDX: 3.78 (+0.18), MNKD: 1.61 (-0.07), PDLI: 3.33 (+0.16)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MannKind Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 15, 2016 - MNKD
GlobeNewswire - Fri Mar 11, 10:54AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
MNKD: 1.61 (-0.07)
March 15 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Lawsuit Against MannKind Corp.
BusinessWire - Fri Mar 11, 10:30AM CST
Glancy Prongay & Murray LLP ("GPM"
reminds investors of the upcoming March 15, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class" of investors who purchased MannKind Corp. ("MannKind" or the "Company" (NASDAQ: MNKD) securities between August 10, 2015 and January 5, 2016, inclusive (the "Class Period". MannKind investors are encouraged to contact Casey Sadler, Esquire, to discuss their legal rights. MNKD: 1.61 (-0.07)
MannKind (MNKD) Stock Spiked Ahead of Q4 Earnings
at The Street - Thu Mar 10, 3:04PM CST
MannKind (MNKD) shares closed Thursday's trading session up ahead of the company's 2015 fourth quarter financial results.
MNKD: 1.61 (-0.07)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving MannKind Corp. and a Lead Plaintiff Deadline of March 15, 2016 - MNKD
GlobeNewswire - Wed Mar 09, 9:16AM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp. (Nasdaq:MNKD) securities between August 10, 2015 and January 5, 2016.
MNKD: 1.61 (-0.07)
